Bristol-Myers Squibb vs. Johnson & Johnson: Quarterly Revenue Comparison
Both Bristol-Myers Squibb and Johnson & Johnson have demonstrated consistent, albeit slow, revenue growth over the past several quarters. While Johnson & Johnson maintains a significantly larger revenue base—approximately double that of Bristol-Myers Squibb—it has also achieved slightly higher year-over-year growth rates during this period. Bristol-Myers Squibb reported $13 billion in Q2 2026 revenue, up from $11.5 billion a year earlier, while Johnson & Johnson reached $25.3 billion for the same quarter, an increase of about $1.6 billion compared to its prior-year performance. J&J's medical technology division is particularly notable, contributing over $33.79 billion in revenue during 2025 and showing a 3.6% growth rate in Q2 2026. Johnson & Johnson has also expanded through strategic acquisitions such as Firefly Bio for its antibody-drug conjugate platform and recently received FDA approval for the OTTAVA Robotic Surgical System, which could become a new revenue driver with high profit potential.
Topics: biotech earnings pharmaceuticals regulatory approval